WuXi XDC Delays Dispatch of Composite Document for Voluntary Cash Offers

The latest announcement is out from WuXi XDC Cayman, Inc. ( (HK:2268) ).

WuXi XDC Cayman Inc., together with offeror BioDlink International Company Limited and associate WuXi Biologics, has announced a delay in sending a composite offer document related to voluntary conditional cash offers for all issued shares not already owned by the offeror and for the cancellation of all outstanding share options. The parties have applied for, and expect to receive, regulatory consent to extend the deadline for dispatching this composite document from 4 February 2026 to on or before 13 February 2026, as they need more time to finalize independent financial advice and indebtedness disclosures; until the conditions of the offers are satisfied or waived, completion remains uncertain and shareholders and option holders are urged to await the composite document and exercise caution in dealing in the company’s securities.

The most recent analyst rating on (HK:2268) stock is a Hold with a HK$65.00 price target. To see the full list of analyst forecasts on WuXi XDC Cayman, Inc. stock, see the HK:2268 Stock Forecast page.

More about WuXi XDC Cayman, Inc.

WuXi XDC Cayman Inc. is a Cayman Islands–incorporated company associated with WuXi Biologics and operates in the biopharmaceutical and biologics-related services sector. The company is involved in advanced drug development and manufacturing services, positioning itself within the broader life sciences and contract development and manufacturing organization (CDMO) industry, with its shares listed in Hong Kong.

Average Trading Volume: 4,317,151

Technical Sentiment Signal: Buy

Current Market Cap: HK$75.61B

For a thorough assessment of 2268 stock, go to TipRanks’ Stock Analysis page.